Prostate cancerStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) - MK-5684-003 - Merck Sharp & Dohme LLC
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer - rechARge - Celgene
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). - MEVPRO-1 - Pfizer
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. - MEVPRO-2 - Pfizer
